Exhaled nitric oxide: A marker of pulmonary hemodynamics in heart failure

Joshua M. Hare, Geoffrey C. Nguyen, Anthony F. Massaro, Jeffrey M. Drazen, Lynne W. Stevenson, Wilson S. Colucci, James C. Fang, Wendy Johnson, Michael M. Givertz, Caroline Lucas

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: We sought to test the hypothesis that patients with decompensated heart failure (HF) lose a compensatory process whereby nitric oxide (NO) maintains pulmonary vascular tone. BACKGROUND: Exhaled nitric oxide (eNO) partially reflects vascular endothelial NO release. Levels of eNO are elevated in patients with compensated HF and correlate inversely with pulmonary artery pressures (PAP), reflecting pulmonary vasodilatory activity. METHODS: We measured the mean mixed expired NO content of a vital-capacity breath using chemiluminescence in patients with compensated HF (n = 30), decompensated HF (n = 7) and in normal control subjects (n = 90). Pulmonary artery pressures were also measured in patients with HF. The eNO and PAP were determined sequentially during therapy with intravenous vasodilators in patients with decompensated HF (n = 7) and in an additional group of patients with HF (n = 13) before and during administration of milrinone. RESULTS: The eNO was higher in patients with HF than in control subjects (9.9 ± 1.1 ppb vs. 6.2 ± 0.4 ppb, p = 0.002) and inversely correlated with PAP (r = -0.81, p <0.00001). In marked contrast, patients with decompensated HF exhibited even higher levels of eNO (20.4 ± 6.2 ppb) and PAP, but there was a loss of the inverse relationship between these two variables. During therapy (7.3 ± 6 days) with sodium nitroprusside and diuresis, hemodynamics improved, eNO concentrations fell (11.2 ± 1.2 ppb vs. before treatment, p <0.05), and the relationship between eNO and PAP was restored. After milrinone, eNO rose proportionally with decreased PAP (p <0.05). CONCLUSIONS: Elevated eNO may reflect a compensatory circulatory mechanism in HF that is lost in patients with clinically decompensated HF. The eNO may be an easily obtainable and quantifiable measure of the response to therapy in advanced HF.

Original languageEnglish (US)
Pages (from-to)1114-1119
Number of pages6
JournalJournal of the American College of Cardiology
Volume40
Issue number6
DOIs
StatePublished - Sep 18 2002

Fingerprint

Nitric Oxide
Heart Failure
Hemodynamics
Lung
Pulmonary Artery
Pressure
Milrinone
Blood Vessels
Diuresis
Vital Capacity
Nitroprusside
Therapeutics
Luminescence
Vasodilator Agents

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Hare, J. M., Nguyen, G. C., Massaro, A. F., Drazen, J. M., Stevenson, L. W., Colucci, W. S., ... Lucas, C. (2002). Exhaled nitric oxide: A marker of pulmonary hemodynamics in heart failure. Journal of the American College of Cardiology, 40(6), 1114-1119. https://doi.org/10.1016/S0735-1097(02)02117-4

Exhaled nitric oxide : A marker of pulmonary hemodynamics in heart failure. / Hare, Joshua M.; Nguyen, Geoffrey C.; Massaro, Anthony F.; Drazen, Jeffrey M.; Stevenson, Lynne W.; Colucci, Wilson S.; Fang, James C.; Johnson, Wendy; Givertz, Michael M.; Lucas, Caroline.

In: Journal of the American College of Cardiology, Vol. 40, No. 6, 18.09.2002, p. 1114-1119.

Research output: Contribution to journalArticle

Hare, JM, Nguyen, GC, Massaro, AF, Drazen, JM, Stevenson, LW, Colucci, WS, Fang, JC, Johnson, W, Givertz, MM & Lucas, C 2002, 'Exhaled nitric oxide: A marker of pulmonary hemodynamics in heart failure', Journal of the American College of Cardiology, vol. 40, no. 6, pp. 1114-1119. https://doi.org/10.1016/S0735-1097(02)02117-4
Hare, Joshua M. ; Nguyen, Geoffrey C. ; Massaro, Anthony F. ; Drazen, Jeffrey M. ; Stevenson, Lynne W. ; Colucci, Wilson S. ; Fang, James C. ; Johnson, Wendy ; Givertz, Michael M. ; Lucas, Caroline. / Exhaled nitric oxide : A marker of pulmonary hemodynamics in heart failure. In: Journal of the American College of Cardiology. 2002 ; Vol. 40, No. 6. pp. 1114-1119.
@article{4ad8b2b625ff4e67a014483f083c786f,
title = "Exhaled nitric oxide: A marker of pulmonary hemodynamics in heart failure",
abstract = "OBJECTIVES: We sought to test the hypothesis that patients with decompensated heart failure (HF) lose a compensatory process whereby nitric oxide (NO) maintains pulmonary vascular tone. BACKGROUND: Exhaled nitric oxide (eNO) partially reflects vascular endothelial NO release. Levels of eNO are elevated in patients with compensated HF and correlate inversely with pulmonary artery pressures (PAP), reflecting pulmonary vasodilatory activity. METHODS: We measured the mean mixed expired NO content of a vital-capacity breath using chemiluminescence in patients with compensated HF (n = 30), decompensated HF (n = 7) and in normal control subjects (n = 90). Pulmonary artery pressures were also measured in patients with HF. The eNO and PAP were determined sequentially during therapy with intravenous vasodilators in patients with decompensated HF (n = 7) and in an additional group of patients with HF (n = 13) before and during administration of milrinone. RESULTS: The eNO was higher in patients with HF than in control subjects (9.9 ± 1.1 ppb vs. 6.2 ± 0.4 ppb, p = 0.002) and inversely correlated with PAP (r = -0.81, p <0.00001). In marked contrast, patients with decompensated HF exhibited even higher levels of eNO (20.4 ± 6.2 ppb) and PAP, but there was a loss of the inverse relationship between these two variables. During therapy (7.3 ± 6 days) with sodium nitroprusside and diuresis, hemodynamics improved, eNO concentrations fell (11.2 ± 1.2 ppb vs. before treatment, p <0.05), and the relationship between eNO and PAP was restored. After milrinone, eNO rose proportionally with decreased PAP (p <0.05). CONCLUSIONS: Elevated eNO may reflect a compensatory circulatory mechanism in HF that is lost in patients with clinically decompensated HF. The eNO may be an easily obtainable and quantifiable measure of the response to therapy in advanced HF.",
author = "Hare, {Joshua M.} and Nguyen, {Geoffrey C.} and Massaro, {Anthony F.} and Drazen, {Jeffrey M.} and Stevenson, {Lynne W.} and Colucci, {Wilson S.} and Fang, {James C.} and Wendy Johnson and Givertz, {Michael M.} and Caroline Lucas",
year = "2002",
month = "9",
day = "18",
doi = "10.1016/S0735-1097(02)02117-4",
language = "English (US)",
volume = "40",
pages = "1114--1119",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Exhaled nitric oxide

T2 - A marker of pulmonary hemodynamics in heart failure

AU - Hare, Joshua M.

AU - Nguyen, Geoffrey C.

AU - Massaro, Anthony F.

AU - Drazen, Jeffrey M.

AU - Stevenson, Lynne W.

AU - Colucci, Wilson S.

AU - Fang, James C.

AU - Johnson, Wendy

AU - Givertz, Michael M.

AU - Lucas, Caroline

PY - 2002/9/18

Y1 - 2002/9/18

N2 - OBJECTIVES: We sought to test the hypothesis that patients with decompensated heart failure (HF) lose a compensatory process whereby nitric oxide (NO) maintains pulmonary vascular tone. BACKGROUND: Exhaled nitric oxide (eNO) partially reflects vascular endothelial NO release. Levels of eNO are elevated in patients with compensated HF and correlate inversely with pulmonary artery pressures (PAP), reflecting pulmonary vasodilatory activity. METHODS: We measured the mean mixed expired NO content of a vital-capacity breath using chemiluminescence in patients with compensated HF (n = 30), decompensated HF (n = 7) and in normal control subjects (n = 90). Pulmonary artery pressures were also measured in patients with HF. The eNO and PAP were determined sequentially during therapy with intravenous vasodilators in patients with decompensated HF (n = 7) and in an additional group of patients with HF (n = 13) before and during administration of milrinone. RESULTS: The eNO was higher in patients with HF than in control subjects (9.9 ± 1.1 ppb vs. 6.2 ± 0.4 ppb, p = 0.002) and inversely correlated with PAP (r = -0.81, p <0.00001). In marked contrast, patients with decompensated HF exhibited even higher levels of eNO (20.4 ± 6.2 ppb) and PAP, but there was a loss of the inverse relationship between these two variables. During therapy (7.3 ± 6 days) with sodium nitroprusside and diuresis, hemodynamics improved, eNO concentrations fell (11.2 ± 1.2 ppb vs. before treatment, p <0.05), and the relationship between eNO and PAP was restored. After milrinone, eNO rose proportionally with decreased PAP (p <0.05). CONCLUSIONS: Elevated eNO may reflect a compensatory circulatory mechanism in HF that is lost in patients with clinically decompensated HF. The eNO may be an easily obtainable and quantifiable measure of the response to therapy in advanced HF.

AB - OBJECTIVES: We sought to test the hypothesis that patients with decompensated heart failure (HF) lose a compensatory process whereby nitric oxide (NO) maintains pulmonary vascular tone. BACKGROUND: Exhaled nitric oxide (eNO) partially reflects vascular endothelial NO release. Levels of eNO are elevated in patients with compensated HF and correlate inversely with pulmonary artery pressures (PAP), reflecting pulmonary vasodilatory activity. METHODS: We measured the mean mixed expired NO content of a vital-capacity breath using chemiluminescence in patients with compensated HF (n = 30), decompensated HF (n = 7) and in normal control subjects (n = 90). Pulmonary artery pressures were also measured in patients with HF. The eNO and PAP were determined sequentially during therapy with intravenous vasodilators in patients with decompensated HF (n = 7) and in an additional group of patients with HF (n = 13) before and during administration of milrinone. RESULTS: The eNO was higher in patients with HF than in control subjects (9.9 ± 1.1 ppb vs. 6.2 ± 0.4 ppb, p = 0.002) and inversely correlated with PAP (r = -0.81, p <0.00001). In marked contrast, patients with decompensated HF exhibited even higher levels of eNO (20.4 ± 6.2 ppb) and PAP, but there was a loss of the inverse relationship between these two variables. During therapy (7.3 ± 6 days) with sodium nitroprusside and diuresis, hemodynamics improved, eNO concentrations fell (11.2 ± 1.2 ppb vs. before treatment, p <0.05), and the relationship between eNO and PAP was restored. After milrinone, eNO rose proportionally with decreased PAP (p <0.05). CONCLUSIONS: Elevated eNO may reflect a compensatory circulatory mechanism in HF that is lost in patients with clinically decompensated HF. The eNO may be an easily obtainable and quantifiable measure of the response to therapy in advanced HF.

UR - http://www.scopus.com/inward/record.url?scp=0037130789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037130789&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(02)02117-4

DO - 10.1016/S0735-1097(02)02117-4

M3 - Article

C2 - 12354437

AN - SCOPUS:0037130789

VL - 40

SP - 1114

EP - 1119

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 6

ER -